Roche is close to a $5 billion deal to buy Spark Therapeutics, according to The Wall Street Journal. The deal would allow Switzerland-based Roche to expand its footprint treating hemophilia. (WSJ)

Purdue Pharma and former CEO Richard Sackler allegedly concealed OxyContin’s strength from doctors, according to deposition documents. Sealed testimony from a 2015 case against Sackler and Purdue showed that the company sought to minimize the risk of OxyContin and didn’t correct the false impression of some doctors that the opioid is weaker than morphine. (STAT)

A J&J marketing director said the company has “nothing to hide” in talc lawsuits. Sophie Rasmussen, senior marketing director for its baby-care unit in EMEA, said at a conference that J&J’s response to claims that its baby powder contains asbestos has been focused on “proactive communication and transparency.” (MM&M)

Investment research firm Morningstar has identified pharma companies ripe for M&A. Amgen, Gilead, Johnson & Johnson, Merck, and Pfizer are likely looking for large-scale deals this year, according to the report. AbbVie, Biogen, BioMarin, and Regeneron, meanwhile, have the right combination of smaller size and strong pipelines, making them potential targets. (Endpoints)

Startups offering online prescriptions for erectile dysfunction may be missing more serious conditions in men. Companies such as Hims and Roman say they direct patients to appropriate care, even if not within their organization, but doctors are worried that men getting treatment online means they’re not addressing underlying health problems. (Business Insider)